Department of Obstetrics and Gynecology, Academic Hospital Cologne Weyertal University of Cologne, Weyertal 76, 50931, Cologne, Germany.
Upper Engadin Hospital, Samedan, Switzerland.
Arch Gynecol Obstet. 2022 Jul;306(1):1-6. doi: 10.1007/s00404-022-06516-1.
Uterine fibroids are one of the most common diseases in female patients, lead mainly to bleeding disorders and lower abdominal pain, and reduce the chance of having children. In recent years we have seen a trend towards more and more pharmacotherapies and minimally invasive organ-preserving treatments. One novel and innovative procedure for an organ-preserving treatment of symptomatic uterine fibroids is the transcervical ultrasound-guided radiofrequency ablation (TRFA). TRFA has been used in Germany since 2013 and later found use in other German-speaking countries as well. There have now been more than 1200 TRFA treatments performed in Germany, Austria, and Switzerland. Experts from these three countries came together for a consensus meeting to analyze the significance of the procedure in the overall concept of the treatment of symptomatic uterine fibroids.
子宫肌瘤是女性患者中最常见的疾病之一,主要导致出血紊乱和下腹痛,并降低生育机会。近年来,我们看到越来越多的药物治疗和微创保留器官治疗的趋势。一种针对有症状子宫肌瘤的保留器官的新型创新治疗方法是经阴道超声引导下射频消融术(TRFA)。自 2013 年以来,德国一直在使用 TRFA,后来在其他德语国家也开始使用。目前,德国、奥地利和瑞士已经进行了 1200 多次 TRFA 治疗。来自这三个国家的专家齐聚一堂,召开共识会议,分析该程序在有症状子宫肌瘤治疗整体概念中的意义。